selective androgen receptor modulator


Also found in: Acronyms, Wikipedia.

selective androgen receptor modulator

,

SARM

A class of medications that attach to cellular binding sites for male hormones. They are designed to maximize anabolic effects while limiting side effects. They may be used to treat conditions such as male hypogonadism or age-related bone loss.
Mentioned in ?
References in periodicals archive ?
The company's clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist entering Phase 2 development for hypercholesterolemia and fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes.
Ostarine[TM] is an oral selective androgen receptor modulator that GTx is developing for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.
The company's clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, entering Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist entering Phase 2 development for hypercholesterolemia and fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes.
Ostarine[TM] is a selective androgen receptor modulator that GTx is developing for the prevention and treatment of muscle wasting, a cancer related symptom.
Effect of GTx-024, a selective androgen receptor modulator (SARM), on stair climb performance and quality of life (QOL) in patients with cancer cachexia.
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced the initiation of a Phase I clinical trial with LGD-4033, a next-generation selective androgen receptor modulator (SARM) designed to provide the benefits of androgen receptor stimulation on skeletal muscle and bone without the side effects of currently marketed androgens.
Nasdaq: GTXI) today announced results of a Phase II clinical trial evaluating Ostarine[TM] (MK-2866), an investigational selective androgen receptor modulator (SARM), in patients with cancer induced muscle loss, also known as cancer cachexia.
The use of a selective androgen receptor modulator to improve lean body mass and muscle performance in patients with cancer cachexia"
and GTx are evaluating multiple selective androgen receptor modulator (SARM) product candidates, including Ostarine[TM] (designated by Merck as MK-2866) and MK-0773 for a variety of musculoskeletal wasting indications including sarcopenia and cancer cachexia.
the Men's Health Biotech Company, today announced completion of recruitment of its proof of concept Phase II clinical trial of its first- in-class drug candidate, ostarine, a selective androgen receptor modulator (SARM).
The science behind using selective androgen receptor modulators (SARMs) to address muscle wasting in cancer patients will be presented, as well as GTx's clinical trial design for its ongoing pivotal Phase III clinical trials of enobosarm (a SARM developed by GTx) for the prevention and treatment of muscle wasting in non-small cell lung cancer patients.
In addition to GTx-758, GTx also is developing Ostarine[TM] (GTx-024) and other selective androgen receptor modulators, or SARMs, for cancer cachexia and other muscle wasting diseases.

Full browser ?